Aression of $ TLR_{9} $ in human pulmonary adenocarcinoma cell line A549
Objective Being considered as a bridge between the innate immunity and acquired immunity, Toll-like receptors (TRLs) are very important innate immunity moleculars. Recent researchs on the innate immunity have focused on the relationship between TLRs and human tumor. This paper investgated the expression and significance of $ TLR_{9} $ in human pulmonary adenocarcinoma cell (A549 cell) and human bronchial epithelial cell (HBE cell). Methods After culturing A549 cell and HBE cell in vitro, the expression of $ TLR_{9} $ mRNA and protein in both cells were detected by immunocytochemistry, Real-time Quantitative Reverse Transcriptase-Polymerase Chain Reaction (Real-time Quantitative PCR) and Western blot, respectively. Results By immunocytochemistry staining, $ TLR_{9} $ was mainly expressed in both cells’ cell membrane and endochylema as brown-yellow material. It showed that the expressions of $ TLR_{9} $ mRNA and protein in A549 cell were stronger than those in HBE cell (P < 0.01). Conclusion The results suggest $ TLR_{9} $ might cause the progression of human pulmonary adenocarcinoma, and the mechanism needs to be further investgatied..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2009 |
---|---|
Erschienen: |
2009 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
---|---|
Enthalten in: |
The Chinese-german journal of clinical oncology - 8(2009), 7 vom: Juli, Seite 393-396 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yu, Jun [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: |
---|
Anmerkungen: |
© Springer-Verlag Berlin Heidelberg 2009 |
---|
doi: |
10.1007/s10330-009-0069-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2065855754 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2065855754 | ||
003 | DE-627 | ||
005 | 20230502183028.0 | ||
007 | tu | ||
008 | 200820s2009 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s10330-009-0069-8 |2 doi | |
035 | |a (DE-627)OLC2065855754 | ||
035 | |a (DE-He213)s10330-009-0069-8-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.81$jOnkologie |2 bkl | ||
100 | 1 | |a Yu, Jun |e verfasserin |4 aut | |
245 | 1 | 0 | |a Aression of $ TLR_{9} $ in human pulmonary adenocarcinoma cell line A549 |
264 | 1 | |c 2009 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Springer-Verlag Berlin Heidelberg 2009 | ||
520 | |a Objective Being considered as a bridge between the innate immunity and acquired immunity, Toll-like receptors (TRLs) are very important innate immunity moleculars. Recent researchs on the innate immunity have focused on the relationship between TLRs and human tumor. This paper investgated the expression and significance of $ TLR_{9} $ in human pulmonary adenocarcinoma cell (A549 cell) and human bronchial epithelial cell (HBE cell). Methods After culturing A549 cell and HBE cell in vitro, the expression of $ TLR_{9} $ mRNA and protein in both cells were detected by immunocytochemistry, Real-time Quantitative Reverse Transcriptase-Polymerase Chain Reaction (Real-time Quantitative PCR) and Western blot, respectively. Results By immunocytochemistry staining, $ TLR_{9} $ was mainly expressed in both cells’ cell membrane and endochylema as brown-yellow material. It showed that the expressions of $ TLR_{9} $ mRNA and protein in A549 cell were stronger than those in HBE cell (P < 0.01). Conclusion The results suggest $ TLR_{9} $ might cause the progression of human pulmonary adenocarcinoma, and the mechanism needs to be further investgatied. | ||
700 | 1 | |a Pan, Tiecheng |4 aut | |
700 | 1 | |a Wei, Xiang |4 aut | |
700 | 1 | |a Liu, Ligang |4 aut | |
700 | 1 | |a Hu, Min |4 aut | |
700 | 1 | |a Yuan, Fang |4 aut | |
700 | 1 | |a Li, Jiaduo |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Chinese-german journal of clinical oncology |d Springer-Verlag, 2002 |g 8(2009), 7 vom: Juli, Seite 393-396 |w (DE-627)385030053 |w (DE-600)2141874-3 |w (DE-576)115050922 |x 1610-1979 |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2009 |g number:7 |g month:07 |g pages:393-396 |
856 | 4 | 1 | |u https://doi.org/10.1007/s10330-009-0069-8 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a GBV_ILN_267 | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_4277 | ||
936 | b | k | |a 44.81$jOnkologie |q VZ |0 106409433 |0 (DE-625)106409433 |
951 | |a AR | ||
952 | |d 8 |j 2009 |e 7 |c 07 |h 393-396 |